Anti-Human CTLA-4 (Ipilimumab) [Clone MDX-010]
Anti-Human CTLA-4 (Ipilimumab) [Clone MDX-010] (LT1600-GRP)
Products
Description
Cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) is a protein receptor that serves as an immune checkpoint and down-regulates the immune system. CTLA-4 is constitutively expressed in regulatory T cells but is only upregulated in conventional T cells following activation. Many cancers, including Melanoma, are associated with CTLA-4 upregulation because the body’s ability to recognize and destroy cancer cells is hampered by an inhibitory mechanism. Ipilimumab targets CTLA-4 and works by turning off this inhibitory mechanism and, thus, enhances the body’s own immune response against cancer cells.”2 Emerging research suggests that combined blockade of PD-1 and CTLA-4, with Nivolumab and Ipilimumab respectively, could produce greater antitumor activity than blockade of either pathway alone.1 This cost-effective, research-grade Anti-Human CTLA-4 (Ipilimumab) utilizes the same variable regions from the therapeutic antibody Ipilimumab making it ideal for research projects.
Specifications
| Manufacturer | Leinco Technologies Inc |
|---|---|
| Manufacturer Cat# | LT1600 |
| Concentration | ≥ 5.0 mg/ml |
| Formulation | This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium, calcium or preservatives added. |
| Isotype | IgG1 κ |
| Clone | MDX-010 |
| Target | CTLA-4 |
| Applications | B, CyTOF®, ELISA, FC |
| Antigen | CTLA4 is constitutively expressed in regulatory T cells. |
| Storage | Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. |
| Protein | CTLA-4 |